Merus N.V. (MRUS)

NASDAQ: MRUS · Real-Time Price · USD
94.38
-0.01 (-0.01%)
Oct 8, 2025, 4:00 PM EDT - Market closed
-0.01%
Market Cap7.15B
Revenue (ttm)56.23M
Net Income (ttm)-385.52M
Shares Out 75.78M
EPS (ttm)-5.57
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,562,444
Open94.37
Previous Close94.39
Day's Range94.32 - 94.46
52-Week Range33.19 - 94.56
Beta1.26
AnalystsBuy
Price Target93.72 (-0.7%)
Earnings DateOct 30, 2025

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumor... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 19, 2016
Employees 321
Stock Exchange NASDAQ
Ticker Symbol MRUS
Full Company Profile

Financial Performance

In 2024, Merus's revenue was $36.13 million, a decrease of -17.78% compared to the previous year's $43.95 million. Losses were -$215.33 million, 39.0% more than in 2023.

Financial Statements

Analyst Summary

According to 18 analysts, the average rating for MRUS stock is "Buy." The 12-month stock price target is $93.72, which is a decrease of -0.70% from the latest price.

Price Target
$93.72
(-0.70% downside)
Analyst Consensus: Buy
Stock Forecasts

News

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus...

Other symbols: GMAB
8 days ago - Business Wire

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction re...

Other symbols: GMAB
9 days ago - Benzinga

This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

Genmab will acquire Merus in an all-cash transaction worth around $8 billion.

Other symbols: GMAB
10 days ago - Barrons

Months after cancer drug trial, Merus agrees to be bought at 41% premium

Merus agreed to be bought for a 41% premium, months after a positive trial of a cancer drug.

10 days ago - Market Watch

Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

Denmark's Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday. The deal marks a signi...

Other symbols: GMAB
10 days ago - Invezz

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

Denmark's Genmab has agreed to acquire Merus NV , a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said on Monday.

Other symbols: GMAB
10 days ago - Reuters

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

COPENHAGEN, Denmark & UTRECHT, Netherlands--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to whi...

Other symbols: GMAB
10 days ago - Business Wire

Merus to Present at the 2025 Wells Fargo Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) --  Merus N.V.

6 weeks ago - GlobeNewsWire

Merus to Present at the Canaccord Genuity 45th Annual Growth Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody...

2 months ago - GlobeNewsWire

Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 63% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months

2 months ago - GlobeNewsWire

Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-len...

2 months ago - GlobeNewsWire

Merus Global Investments Strengthens Leadership and Expands Talent Bench with Strategic Hires and Key Promotions

NEW YORK--(BUSINESS WIRE)--Merus Global Investments (“Merus”), a multi-strategy investment partnership, today unveiled its refreshed website and announced a series of senior promotions and strategic a...

2 months ago - Business Wire

One of Finland's largest energy storage facilities commissioned in Lappeenranta – Merus Power's EUR 15 million delivery completed

TAMPERE, Finland, July 03, 2025 (GLOBE NEWSWIRE) -- The energy storage facility delivered by Merus Power to Lappeenranta, Finland, has been completed and put into market use on 15 May 2025. The energy...

3 months ago - GlobeNewsWire

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative...

Other symbols: BCAX
4 months ago - Seeking Alpha

Merus CEO: We're really optimistic about the potential for our drug in head and neck cancer

CNBC's Angelica Peebles sits down with Merus CEO Dr. Bill Lundberg to discuss the company's recent positive results in head & neck cancer and what he sees for the future of bispecific antibody drugs

4 months ago - CNBC Television

Merus N.V. Announces Pricing of Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-len...

4 months ago - GlobeNewsWire

Merus N.V. Announces Proposed Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

4 months ago - GlobeNewsWire

Merus to Present at Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

4 months ago - GlobeNewsWire

Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

-  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m. ET UT...

4 months ago - GlobeNewsWire

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

5 months ago - GlobeNewsWire

Merus to Present at BofA Securities 2025 Health Care Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

5 months ago - GlobeNewsWire

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting

5 months ago - GlobeNewsWire

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation

6 months ago - GlobeNewsWire

Merus: Riding The Bispecific Wave In Oncology

Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 millio...

6 months ago - Seeking Alpha

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibod...

6 months ago - GlobeNewsWire